Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI-Reference-Cited by-同舟云学术

Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI

Published:2022-07-10 Issue:5 Volume:40 Page:1041-1055
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Morita‐Fujita Mari¹,Arai Yasuyuki¹²^ORCID,Kondo Tadakazu¹^ORCID,Harada Kaito³,Uchida Naoyuki⁴,Toya Takashi⁵^ORCID,Ozawa Yukiyasu⁶,Fukuda Takahiro⁷,Ota Shuichi⁸,Onizuka Makoto³,Kanda Yoshinobu⁹^ORCID,Maruyama Yumiko¹⁰,Takada Satoru¹¹,Kawakita Toshiro¹²,Ara Takahide¹³,Ichinohe Tatsuo¹⁴,Kimura Takafumi¹⁵,Atsuta Yoshiko¹⁶¹⁷,Kako Shinichi⁹^ORCID

Affiliation:

1. Department of Hematology and Oncology Graduate School of Medicine Kyoto University Kyoto Japan

2. Department of Clinical Laboratory Medicine Graduate School of Medicine Kyoto University Kyoto Japan

3. Department of Hematology and Oncology Tokai University School of Medicine Isehara Japan

4. Department of Hematology Toranomon Hospital Tokyo Japan

5. Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

6. Department of Hematology Japanese Red Cross Nagoya First Hospital Nagoya Japan

7. Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan

8. Department of Hematology Sapporo Hokuyu Hospital Sapporo Japan

9. Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan

10. Department of Hematology University of Tsukuba Hospital Ibaraki Japan

11. Leukemia Research Center Saiseikai Maebashi Hospital Maebashi Japan

12. Department of Hematology National Hospital Organization Kumamoto Medical Center Kumamoto Japan

13. Department of Hematology Hokkaido University Hospital Sapporo Japan

14. Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan

15. Preparation Department Japanese Red Cross Kinki Block Blood Center Osaka Japan

16. Japanese Data Center for Hematopoietic Cell Transplantation Nagakute Japan

17. Department of Registry Science for Transplant and Cellular Therapy Aichi Medical University School of Medicine Nagakute Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3046

Reference29 articles.

1. Fractionated total‐body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high‐risk or advanced‐stage hematological malignancies;Long GD;Biol Blood Marrow Transpl,1997

2. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia

3. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia

4. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group

5. High-Dose Etoposide, Cyclophosphamide and Total Body Irradiation with Allogeneic Bone Marrow Transplantation for Resistant Acute Myeloid Leukemia: A Study by the North American Marrow Transplant Group

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Conditioning Regimens and Graft-versus-Host Disease Prophylaxis on the Outcomes of Umbilical Cord Blood Transplantation Performed with Cyclophosphamide/Total Body Irradiation-Based Regimens;Transplantation and Cellular Therapy;2023-12

2. Medium-dose etoposide, cyclophosphamide and total body irradiation conditioning potentiates anti-leukemia immunity in adults with acute lymphoblastic leukemia without aggravating graft-versus-host disease;Cytotherapy;2023-12